Advertisement
Advertisement
U.S. Markets open in 1 hr 30 mins
Advertisement
Advertisement
Advertisement
Advertisement

Genomic Vision Société Anonyme (G09.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0421-0.0009 (-2.09%)
As of 08:05AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0430
Open0.0421
Bid0.0482 x 52900
Ask0.0690 x 51900
Day's Range0.0421 - 0.0421
52 Week Range0.0403 - 0.2732
Volume3,000
Avg. Volume0
Market Cap2.294M
Beta (5Y Monthly)-0.06
PE Ratio (TTM)N/A
EPS (TTM)-0.1190
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research

    GENOMICS | GENETICS | R&D | DIAGNOSIS TESTS Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer® Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops tools and services for the highly accurate characterization of DNA sequences, is pleased to announce a

  • Business Wire

    Genomic Vision and Cambridge Consultants, Part of Capgemini, Announce the Development of an Innovative Technology Platform for In-depth Genomic Analysis

    BAGNEUX, France & CAMBRIDGE, England, November 07, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV, – the "Company") (Paris:GV), a Euronext-listed biotechnology company developing tools and services for the highly accurate characterization of DNA sequences, is pleased to announce the selection of Cambridge Consutants, a world-leading product development and technology consultancy, part of Capgemini Invent1, to jointly develop the next generation of a technology platform for the analysis

  • Business Wire

    Genomic Vision: Financial Information for the Third Quarter of 2022

    BAGNEUX, France, October 27, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV, – the "Company") (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced its revenue and cash position for the nine-month ended on September 30, 2022.

Advertisement
Advertisement